BMCC-2022-V05

Vaccine Antigens against Acinetobacter baumannii

BMCC

Novel Antigens for Preventing the Nosocomial Bacterial Infection

未定中標題
BMCC Targeted indication

Prevention of A. baumannii infection

BMCC Status

Proof of concept/preclinical studies

BMCC Key features
  • Conserved virulence factors
  • Eliciting long-term immunity
  • No obvious side effects
BMCC Market

Antimicrobial resistance has evolved to become a worldwide health threat. According to the RAND EUROPE reports, drug-resistant superbugs will kill more people than cancer and cost up to $100 trillion by 2050. Bacteria that cause nosocomial infection including  Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae are classified by WHO as the priority 1 pathogens which new drugs are most urgently needed.

 

Vaccination is the most effective strategy to prevent infectious diseases.

The COVID-19 pandemics reminds us that life is unpredictable. New diseases and accidents may happen suddenly. Vaccination with A. baumannii vaccine may protect individuals from the nosocomial infections or at least to reduce the disease severity when hospitalized.

MODE OF ACTION

EXPERIMENTAL RESULTS

in vitro efficacy
1.   Expression of NcsP and TonB-R are upregulated in the deficient of iron conditions.
2.   Overexpression of Pase1 increases the virulence of A. baumannii in a cell model and reduces the matured biofilm mass.
3.   Overexpression of Pase2 increases the A. baumannii survival in the presence of H2O2.
4.   GP1 possesses lysozyme activity and eliciting long-term immunity.
in vivo efficacy

The vaccine potential of each antigen has been demonstrated by immunizing mice with the individual antigen three times and then challenging with the reference strain ATCC 17978 or a hypervirulent strain.

Safety pharmacology and general toxicology
1.   No apparent side effects were observed in mice after immunization.
2.   No cytotoxicity was observed when treating human cells A549 with 100 µg/mL of the vaccine antigens.

INTELLECTUAL PROPERTY

Patent: Taiwan, Japan, and USA Pending: EP

SELECTED PUBLICATIONS

NA

BUSINESS OPPORTUNITY

License and/or Collaboration and Sponsored Research

CONTACT

service@biip-dcc.org

*欲下載完整檔案請 登入/ 會員註冊